BACKGROUND: The incidence of type 2 diabetes increases with age. It is unknown whether interventions to prevent diabetes are as effective in elderly persons as in younger adults. METHODS: The Diabetes Prevention Program (DPP) demonstrated that an intensive lifestyle intervention (ILS) or metformin could prevent or delay diabetes. A predefined secondary outcome of DPP was to determine if treatment effects varied by age. RESULTS: At baseline, participants aged 60-85 years were leaner and had the best insulin sensitivity and lowest insulin secretion compared to younger age groups. Diabetes incidence rates did not differ by age in the placebo group, but ILS was more effective with increasing age (6.3, 4.9, and 3.3 cases per 100 person-years, in the 25-44, 45-59, and 60-85 year age groups, respectively; p(trend) =.007). Participants aged 60-85 years had the most weight loss and metabolic equivalent (MET)-hours of physical activity. The metformin group showed a trend toward higher diabetes incidence among older participants (6.7, 7.7, and 9.3 cases per 100 person-years in the 25-44, 45-59, and 60-85 year age groups, respectively; p(trend) =.07); and diabetes risk increased with age (hazard ratio [age 60-85 vs 25-44] 1.63, p =.02), after adjusting for the greater weight loss in the 60-85 year age group. CONCLUSIONS: Lifestyle modification was exceptionally effective in preventing diabetes in older individuals; this finding was largely explained by greater weight loss and physical activity. The limited effectiveness of metformin in older persons may reflect age-related differences in insulin action and secretion. A lifestyle modification program can be recommended for older individuals at high risk for type 2 diabetes.
RCT Entities:
BACKGROUND: The incidence of type 2 diabetes increases with age. It is unknown whether interventions to prevent diabetes are as effective in elderly persons as in younger adults. METHODS: The Diabetes Prevention Program (DPP) demonstrated that an intensive lifestyle intervention (ILS) or metformin could prevent or delay diabetes. A predefined secondary outcome of DPP was to determine if treatment effects varied by age. RESULTS: At baseline, participants aged 60-85 years were leaner and had the best insulin sensitivity and lowest insulin secretion compared to younger age groups. Diabetes incidence rates did not differ by age in the placebo group, but ILS was more effective with increasing age (6.3, 4.9, and 3.3 cases per 100 person-years, in the 25-44, 45-59, and 60-85 year age groups, respectively; p(trend) =.007). Participants aged 60-85 years had the most weight loss and metabolic equivalent (MET)-hours of physical activity. The metformin group showed a trend toward higher diabetes incidence among older participants (6.7, 7.7, and 9.3 cases per 100 person-years in the 25-44, 45-59, and 60-85 year age groups, respectively; p(trend) =.07); and diabetes risk increased with age (hazard ratio [age 60-85 vs 25-44] 1.63, p =.02), after adjusting for the greater weight loss in the 60-85 year age group. CONCLUSIONS: Lifestyle modification was exceptionally effective in preventing diabetes in older individuals; this finding was largely explained by greater weight loss and physical activity. The limited effectiveness of metformin in older persons may reflect age-related differences in insulin action and secretion. A lifestyle modification program can be recommended for older individuals at high risk for type 2 diabetes.
Authors: S E Kahn; V G Larson; J C Beard; K C Cain; G W Fellingham; R S Schwartz; R C Veith; J R Stratton; M D Cerqueira; I B Abrass Journal: Am J Physiol Date: 1990-06
Authors: M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt Journal: Diabetes Care Date: 1998-04 Impact factor: 19.112
Authors: X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard Journal: Diabetes Care Date: 1997-04 Impact factor: 19.112
Authors: Nadine R Sahyoun; Amy L Anderson; Frances A Tylavsky; Jung Sun Lee; Deborah E Sellmeyer; Tamara B Harris Journal: Am J Clin Nutr Date: 2008-01 Impact factor: 7.045
Authors: Jill P Crandall; William C Knowler; Steven E Kahn; David Marrero; Jose C Florez; George A Bray; Steven M Haffner; Mary Hoskin; David M Nathan Journal: Nat Clin Pract Endocrinol Metab Date: 2008-05-20
Authors: John Bellettiere; Genevieve N Healy; Michael J LaMonte; Jacqueline Kerr; Kelly R Evenson; Eileen Rillamas-Sun; Chongzhi Di; David M Buchner; Melbourne F Hovell; Andrea Z LaCroix Journal: J Gerontol A Biol Sci Med Sci Date: 2019-02-15 Impact factor: 6.053
Authors: F M Finucane; S J Sharp; L R Purslow; K Horton; J Horton; D B Savage; S Brage; H Besson; E De Lucia Rolfe; A Sleigh; H J Martin; A Aihie Sayer; C Cooper; U Ekelund; S J Griffin; N J Wareham Journal: Diabetologia Date: 2010-01-06 Impact factor: 10.122
Authors: Leigh Perreault; Steven E Kahn; Costas A Christophi; William C Knowler; Richard F Hamman Journal: Diabetes Care Date: 2009-07-08 Impact factor: 19.112